NCT05495243View on ClinicalTrials.gov

Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 3, 2022

Primary Completion Date

February 1, 2024

Study Completion Date

February 1, 2024

Conditions
Non-cystic Fibrosis Bronchiectasis
Interventions
DRUG

ARINA-1

ARINA-1 (88 mg/mL ascorbic acid, ASC; 150 mg/mL reduced glutathione, GSH)

DRUG

Placebo

Isotonic saline (0.9%)

Trial Locations (10)

19107

Jefferson Hospital, Philadelphia

20007

Georgetown University, Washington D.C.

21205

Johns Hopkins, Baltimore

27103

Southeastern Research Center, Winston-Salem

29425

Medical University of South Carolina, Charleston

University of Texas - Tyler, Tyler

35294

University of Alabama - Birmingham, Birmingham

70803

Louisiana State University, New Orleans

80206

National Jewish Hospital, Denver

97239

Oregon Health and Science University, Portland

All Listed Sponsors
lead

Renovion, Inc.

INDUSTRY